Novel is a technology company with a mission to develop high throughput bacterial platforms in the biotechnology domain. We have selected the plamsid DNA and gene therapy space as our first vertical.
Plasmid DNA (pDNA) signifies a critical starting point for many genetic engineering tasks.
Continued progress in the gene therapy and DNA/RNA based therapeutic space has led to bottlenecks and growing demands for reliable pDNA material suitable for all applications.
We are developing a high throughput platform that is safer, scalable, adaptable to different plasmid backbones, yields higher quality plasmids, and is many times more productive than E.coli.
Process pDNA without relying on antibiotics.
2-17 times more productive than E.Coli based technology.
Capable of handling large and complex plasmid constructs.
Cycle times can be reduced from months to weeks.
No major changes to your current manufacturing infrastructure required.
Platform is entirely bacterial based, meaning no regulatory hurdles.